autologous anti-ALK CAR T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ALK CAR T-cell recognize and induce selective toxicity against ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.